HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Results of long-term D-penicillamine therapy in chronic polyarthritis].

Abstract
In 34 patients with severe rheumatoid arthritis the therapeutic efficacy of 600 mg/die of D-penicillamine was evaluated for five years. Patients were included in the study only if the duration of their disease exceeded 6 months (upper limit 12 months), and there was involvement of 6 or more joints and an elevated erythrocyte sedimentation rate (1 Hour values greater than or equal to 25 mm). In 9 patients (26%) a decline in the activity index could be observed, but 7 of these subjects had a deterioration of findings as assessed by x-ray. The increase of the activity index indicated no therapeutic benefit in 25 patients (74%), which could be confirmed in all subjects by x-ray.
AuthorsH Rautenstrauch, W Laschner, J G Saal, P Fritz
JournalZeitschrift fur Rheumatologie (Z Rheumatol) 1986 Nov-Dec Vol. 45 Issue 6 Pg. 319-21 ISSN: 0340-1855 [Print] Germany
Vernacular TitleErgebnisse der D-Penicillamin-Langzeittherapie bei chronischer Polyarthritis.
PMID3103349 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Penicillamine
Topics
  • Adult
  • Aged
  • Arthritis, Rheumatoid (drug therapy)
  • Female
  • Humans
  • Joints (drug effects)
  • Long-Term Care
  • Male
  • Middle Aged
  • Penicillamine (therapeutic use)
  • Synovial Membrane (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: